JP2021038228A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021038228A5 JP2021038228A5 JP2020180340A JP2020180340A JP2021038228A5 JP 2021038228 A5 JP2021038228 A5 JP 2021038228A5 JP 2020180340 A JP2020180340 A JP 2020180340A JP 2020180340 A JP2020180340 A JP 2020180340A JP 2021038228 A5 JP2021038228 A5 JP 2021038228A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- oxo
- methyl
- difluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- -1 azepine-7-yl Chemical group 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 5
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 206010011878 Deafness Diseases 0.000 claims 3
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 claims 3
- 210000003030 auditory receptor cell Anatomy 0.000 claims 3
- 239000003540 gamma secretase inhibitor Substances 0.000 claims 3
- 231100000888 hearing loss Toxicity 0.000 claims 3
- 230000010370 hearing loss Effects 0.000 claims 3
- 208000016354 hearing loss disease Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 231100000199 ototoxic Toxicity 0.000 claims 3
- 230000002970 ototoxic effect Effects 0.000 claims 3
- PKXWXXPNHIWQHW-RCBQFDQVSA-N (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound C1CN(C)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](O)C(C)C)C2=CC=CC=C21 PKXWXXPNHIWQHW-RCBQFDQVSA-N 0.000 claims 2
- IZAOBRWCUGOKNH-OAHLLOKOSA-N 4-[2-[(1R)-1-(N-(4-chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](C)C=1C(=CC(F)=CC=1)CCCC(O)=O)C1=CC(F)=CC=C1F IZAOBRWCUGOKNH-OAHLLOKOSA-N 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- KJSSPOWBVHTGDG-UHFFFAOYSA-N 2-(2,2,3,3,3-pentafluoropropyl)propanediamide Chemical compound NC(=O)C(C(N)=O)CC(F)(F)C(F)(F)F KJSSPOWBVHTGDG-UHFFFAOYSA-N 0.000 claims 1
- XCGJIFAKUZNNOR-UHFFFAOYSA-N 3-[4-(4-chlorophenyl)sulfonyl-4-(2,5-difluorophenyl)cyclohexyl]propanoic acid Chemical compound C1CC(CCC(=O)O)CCC1(S(=O)(=O)C=1C=CC(Cl)=CC=1)C1=CC(F)=CC=C1F XCGJIFAKUZNNOR-UHFFFAOYSA-N 0.000 claims 1
- XEAOPVUAMONVLA-QGZVFWFLSA-N Avagacestat Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](CCC(F)(F)F)C(=O)N)CC(C(=C1)F)=CC=C1C=1N=CON=1 XEAOPVUAMONVLA-QGZVFWFLSA-N 0.000 claims 1
- DWJXYEABWRJFSP-XOBRGWDASA-N DAPT Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 DWJXYEABWRJFSP-XOBRGWDASA-N 0.000 claims 1
- NGBKFLTYGSREKK-PMACEKPBSA-N Z-Val-Phe-H Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C(=O)OCC1=CC=CC=C1 NGBKFLTYGSREKK-PMACEKPBSA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 1
- 108010007877 calpain inhibitor III Proteins 0.000 claims 1
- 230000006727 cell loss Effects 0.000 claims 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 claims 1
- 125000004212 difluorophenyl group Chemical group 0.000 claims 1
- 238000011977 dual antiplatelet therapy Methods 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229950001900 semagacestat Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- SJMDMGHPMLKLHQ-UHFFFAOYSA-N tert-butyl 2-aminoacetate Chemical compound CC(C)(C)OC(=O)CN SJMDMGHPMLKLHQ-UHFFFAOYSA-N 0.000 claims 1
- MURCDOXDAHPNRQ-PJRHAEEISA-N tert-butyl n-[(2s,3r,5s)-6-[[(2s)-1-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-benzyl-3-hydroxy-6-oxo-1-phenylhexan-2-yl]carbamate Chemical compound C([C@@H]([C@H](O)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)C1=CC=CC=C1 MURCDOXDAHPNRQ-PJRHAEEISA-N 0.000 claims 1
- 229920000428 triblock copolymer Polymers 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022069599A JP2022109965A (ja) | 2012-09-07 | 2022-04-20 | 聴覚喪失治療 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261698475P | 2012-09-07 | 2012-09-07 | |
| US61/698,475 | 2012-09-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019091552A Division JP2019172679A (ja) | 2012-09-07 | 2019-05-14 | 聴覚喪失治療 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022069599A Division JP2022109965A (ja) | 2012-09-07 | 2022-04-20 | 聴覚喪失治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021038228A JP2021038228A (ja) | 2021-03-11 |
| JP2021038228A5 true JP2021038228A5 (enExample) | 2021-07-26 |
Family
ID=50237627
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531223A Withdrawn JP2015527398A (ja) | 2012-09-07 | 2013-09-06 | 聴覚喪失治療 |
| JP2019091552A Withdrawn JP2019172679A (ja) | 2012-09-07 | 2019-05-14 | 聴覚喪失治療 |
| JP2020180340A Withdrawn JP2021038228A (ja) | 2012-09-07 | 2020-10-28 | 聴覚喪失治療 |
| JP2022069599A Pending JP2022109965A (ja) | 2012-09-07 | 2022-04-20 | 聴覚喪失治療 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531223A Withdrawn JP2015527398A (ja) | 2012-09-07 | 2013-09-06 | 聴覚喪失治療 |
| JP2019091552A Withdrawn JP2019172679A (ja) | 2012-09-07 | 2019-05-14 | 聴覚喪失治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022069599A Pending JP2022109965A (ja) | 2012-09-07 | 2022-04-20 | 聴覚喪失治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20150209367A1 (enExample) |
| EP (2) | EP3970725B1 (enExample) |
| JP (4) | JP2015527398A (enExample) |
| AU (1) | AU2013312358B2 (enExample) |
| CA (1) | CA2883896C (enExample) |
| HK (1) | HK1211875A1 (enExample) |
| WO (1) | WO2014039781A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2669693C (en) | 2006-11-15 | 2018-06-12 | Massachusetts Eye & Ear Infirmary | Generation of inner ear cells |
| AU2013312358B2 (en) * | 2012-09-07 | 2018-08-09 | Massachusetts Eye & Ear Infirmary | Treating hearing loss |
| TWI625332B (zh) * | 2015-07-07 | 2018-06-01 | 美國禮來大藥廠 | 刻痕(notch)路徑傳訊抑制化合物 |
| US20180326080A1 (en) * | 2015-10-27 | 2018-11-15 | Purdue Research Foundation | Polymer-based therapeutics for inductive browning of fat |
| RU2707284C1 (ru) * | 2015-10-30 | 2019-11-26 | Пайплайн Терапьютикс, Инк. | Дибензоазепиновые соединения и их применение для лечения ушных заболеваний и нарушений |
| US11185536B2 (en) | 2015-12-04 | 2021-11-30 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
| CN109219439B (zh) | 2016-01-29 | 2022-09-20 | 马萨诸塞眼科耳科诊所 | 内耳支持细胞的扩增和分化及其使用方法 |
| CN109689027A (zh) | 2016-06-29 | 2019-04-26 | 奥德纳米有限公司 | 甘油三酯耳用制剂及其用途 |
| CN110248650A (zh) | 2016-10-31 | 2019-09-17 | 霍夫耳科研究所 | 用于增强突触发生和神经突发生的方法 |
| KR20190098998A (ko) * | 2016-12-16 | 2019-08-23 | 파이프라인 테라퓨틱스, 아이엔씨. | 달팽이관 시냅스질환의 치료 방법 |
| JP2022504265A (ja) | 2018-10-02 | 2022-01-13 | フリークエンシー セラピューティクス インコーポレイテッド | 耳治療薬に関する医薬組成物及び方法 |
| TW202103692A (zh) | 2019-04-08 | 2021-02-01 | 美商頻率醫療公司 | 用於治療聽力損失之組合物及方法 |
| TWI781536B (zh) | 2021-02-26 | 2022-10-21 | 國立臺灣科技大學 | 藥物釋放組合物、其製造方法及其用途 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| USD309535S (en) | 1987-03-30 | 1990-07-31 | Chromcraft Furniture Corp. | Chair |
| USD360535S (en) | 1994-02-14 | 1995-07-25 | Staffan Sjoberg | Combined beach chair and beach mattress |
| US6635632B1 (en) | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| DK0951466T3 (da) | 1996-12-23 | 2009-03-16 | Elan Pharm Inc | Cycloalkyl-, lactam, lacton- og beslægtede forbindelser, farmaceutiske sammensætninger, der omfatter samme, og fremgangsmåder til inhibering af beta-amyloidpeptidfrigivelse og/eller dets syntese ved anvendelse af sådanne forbindelser |
| US6683048B1 (en) | 1997-04-10 | 2004-01-27 | Mcgill University | Compounds and methods for stimulating gene expression and cellular differentiation |
| KR100581199B1 (ko) | 1998-06-19 | 2006-05-17 | 카이론 코포레이션 | 글리코겐 신타제 키나제 3의 억제제 |
| AU4206200A (en) | 1999-04-05 | 2000-10-23 | Adherex Technologies Inc. | Compounds and methods for stimulating beta-catenin mediated gene expression and differentiation |
| ATE384704T1 (de) | 1999-12-17 | 2008-02-15 | Novartis Vaccines & Diagnostic | Pyrazin-basierte hemmer der glycogen-synthase- kinase 3 |
| AU779875B2 (en) | 2000-01-24 | 2005-02-17 | Merck Sharp & Dohme Limited | Gamma-secretase inhibitors |
| GB0005251D0 (en) | 2000-03-03 | 2000-04-26 | Merck Sharp & Dohme | Therapeutic compounds |
| US7365196B2 (en) | 2000-03-20 | 2008-04-29 | Merck Sharp & Dohme Ltd. | Sulphonamido-substituted bridged bicycloalkyl derivatives |
| GB0008710D0 (en) | 2000-04-07 | 2000-05-31 | Merck Sharp & Dohme | Therapeutic compounds |
| USD447031S1 (en) | 2000-04-20 | 2001-08-28 | Wang Keaun Oh | Hand carry air tacker |
| CA2412764C (en) | 2000-07-11 | 2014-06-03 | Sound Pharmaceuticals Incorporated | Stimulation of cellular regeneration and differentiation in the inner ear |
| US7399633B2 (en) | 2000-10-27 | 2008-07-15 | Fred Hutchinson Cancer Research Center | Methods for immortalizing cells |
| AU1074702A (en) | 2000-11-02 | 2002-05-15 | Merck Sharp & Dohme | Sulfamides as gamma-secretase inhibitors |
| US7468365B2 (en) | 2000-11-17 | 2008-12-23 | Eli Lilly And Company | Lactam compound |
| UA74849C2 (en) | 2000-11-17 | 2006-02-15 | Lilly Co Eli | Lactam |
| US6483732B2 (en) | 2000-12-13 | 2002-11-19 | Koninklijke Philips Electronics N.V. | Relational content addressable memory |
| GB0119152D0 (en) | 2001-08-06 | 2001-09-26 | Merck Sharp & Dohme | Therapeutic agents |
| US7206639B2 (en) | 2002-03-15 | 2007-04-17 | Sarcos Investments Lc | Cochlear drug delivery system and method |
| EP1503998B1 (en) | 2002-05-01 | 2009-07-01 | MERCK SHARP & DOHME LTD. | Heteroaryl substituted spirocyclic sufamides for inhibition of gamma secretase |
| GB0209997D0 (en) | 2002-05-01 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
| GB0209991D0 (en) | 2002-05-01 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
| GB0209995D0 (en) | 2002-05-01 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
| GB0223038D0 (en) | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| GB0223039D0 (en) | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| GB0225474D0 (en) | 2002-11-01 | 2002-12-11 | Merck Sharp & Dohme | Therapeutic agents |
| GB0225475D0 (en) | 2002-11-01 | 2002-12-11 | Merck Sharp & Dohme | Therapeutic agents |
| CA2522176A1 (en) | 2003-03-13 | 2004-09-30 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
| CL2004000647A1 (es) | 2003-03-31 | 2005-02-04 | Wyeth Corp | Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am |
| US20050019801A1 (en) | 2003-06-04 | 2005-01-27 | Curis, Inc. | Stem cell-based methods for identifying and characterizing agents |
| GB0318447D0 (en) | 2003-08-05 | 2003-09-10 | Merck Sharp & Dohme | Therapeutic agents |
| RU2383547C2 (ru) | 2003-08-28 | 2010-03-10 | Чоонгвае Фарма Корпорейшн | Модуляция бета-катенин/tcf-активируемой транскрипции |
| EP1667984B1 (en) | 2003-09-24 | 2011-05-18 | Merck Sharp & Dohme Ltd. | Gamma-secretase inhibitors |
| GB0326039D0 (en) | 2003-11-07 | 2003-12-10 | Merck Sharp & Dohme | Therapeutic agents |
| US8673634B2 (en) | 2003-11-13 | 2014-03-18 | Massachusetts Eye & Ear Infirmary | Method for the treatment of hearing loss |
| CA2554403A1 (en) | 2004-01-27 | 2005-08-11 | Nuvelo, Inc. | Gastrointestinal proliferative factor and uses thereof |
| WO2005072793A1 (en) | 2004-01-29 | 2005-08-11 | The Charles Stark Draper Laboratory, Inc. | Implantable drug delivery apparatus |
| ES2375627T3 (es) | 2004-02-23 | 2012-03-02 | Eli Lilly And Company | Anticuerpos anti-abeta. |
| JP2006117536A (ja) * | 2004-10-19 | 2006-05-11 | Kyoto Univ | 内耳の有毛細胞を誘導するための医薬 |
| WO2007030743A2 (en) | 2005-09-08 | 2007-03-15 | Massachusetts Eye & Ear Infirmary | Cochlear implants containing biological cells and uses thereof |
| US20090306045A1 (en) | 2005-12-22 | 2009-12-10 | Ira Mellman | Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease |
| CA2644136A1 (en) | 2006-02-27 | 2007-09-07 | The Johns Hopkins University | Cancer treatment with gamma-secretase inhibitors |
| WO2007121272A2 (en) * | 2006-04-11 | 2007-10-25 | The Board Of Regents Of The University Of Texas System | Methods and compositions involving nucleotide repeat disorders |
| US8175269B2 (en) | 2006-07-05 | 2012-05-08 | Oracle International Corporation | System and method for enterprise security including symmetric key protection |
| CA2669693C (en) | 2006-11-15 | 2018-06-12 | Massachusetts Eye & Ear Infirmary | Generation of inner ear cells |
| WO2008071605A2 (en) | 2006-12-15 | 2008-06-19 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| CA2694209C (en) | 2007-08-14 | 2013-09-17 | Eli Lilly And Company | Azepine derivatives as gamma-secretase inhibitors |
| WO2009047163A1 (en) | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| CA2710913A1 (en) | 2008-01-11 | 2009-07-16 | F. Hoffmann-La Roche Ag | Use of a gamma-secretase inhibitor for treating cancer |
| EP2732819B1 (en) | 2008-02-07 | 2019-10-16 | Massachusetts Eye & Ear Infirmary | Compounds that enhance Atoh-1 expression |
| EP2278999B1 (en) | 2008-04-21 | 2025-01-29 | Dompé farmaceutici S.p.A. | Auris formulations for treating otic diseases and conditions |
| GB2461186B (en) | 2008-04-21 | 2010-09-01 | Otonomy Inc | Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
| BRPI0912482A2 (pt) | 2008-05-14 | 2020-08-18 | Otonomy, Inc | composições de corticosteróide de liberação controlada e métodos para o tratamento de distúrbios auriculares |
| US8648119B2 (en) * | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
| US8496957B2 (en) | 2008-07-21 | 2013-07-30 | Otonomy, Inc | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
| CA2743436C (en) * | 2008-11-24 | 2017-10-31 | Massachusetts Eye & Ear Infirmary | Pathways to generate hair cells |
| EP2375895A4 (en) | 2008-12-11 | 2012-05-30 | Merck Sharp & Dohme | METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS |
| US8609897B2 (en) | 2009-02-06 | 2013-12-17 | Merck Sharp & Dohme Corp. | Trifluoromethylsulfonamide gamma secretase inhibitor |
| AU2010311035B2 (en) | 2009-10-28 | 2013-05-16 | Pfizer Inc. | Imidazole derivatives as casein kinase inhibitors |
| CA134865S (en) | 2010-02-11 | 2010-11-10 | Hankook Tire Co Ltd | Automobile tire |
| EP2566479B1 (en) | 2010-05-07 | 2014-12-24 | GlaxoSmithKline LLC | Azaindazoles |
| CN102947451B (zh) | 2010-05-26 | 2017-09-22 | 库尔纳公司 | 通过抑制无调同源物1(atoh1)的天然反义转录物而治疗atoh1相关疾病 |
| WO2012018499A2 (en) | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
| RU2456356C1 (ru) | 2011-04-29 | 2012-07-20 | Борис Сергеевич Кустов | Коллоидный раствор наносеребра и способ его получения |
| AU2013312358B2 (en) * | 2012-09-07 | 2018-08-09 | Massachusetts Eye & Ear Infirmary | Treating hearing loss |
| AU2013312305B2 (en) | 2012-09-07 | 2018-06-28 | Massachusetts Eye And Ear Infirmary | Methods and compositions for regenerating hair cells and/or supporting cells |
| CA2905842C (en) | 2013-03-14 | 2023-02-21 | The Brigham And Women's Hospital, Inc. | Compositions and methods for epithelial stem cell expansion comprising a wnt agonist and a histone deacetylase inhibitor |
| US9572815B2 (en) | 2013-03-15 | 2017-02-21 | St. Jude Children's Research Hospital | Methods and compositions of p27KIP1 transcriptional modulators |
| WO2015168149A2 (en) | 2014-04-28 | 2015-11-05 | Massachusetts Eye & Ear Infirmary | Sensorineural hair cell differentiation |
| US20170314027A1 (en) | 2014-08-06 | 2017-11-02 | Massachusetts Eye And Ear Infirmary | Increasing atoh1 life to drive sensorineural hair cell differentiantion |
| TWI625332B (zh) | 2015-07-07 | 2018-06-01 | 美國禮來大藥廠 | 刻痕(notch)路徑傳訊抑制化合物 |
| US11185536B2 (en) | 2015-12-04 | 2021-11-30 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
| US11021687B2 (en) | 2016-01-08 | 2021-06-01 | The Brigham And Women's Hospital, Inc. | Production of differentiated enteroendocrine cells and insulin producing cells |
| CN109219439B (zh) | 2016-01-29 | 2022-09-20 | 马萨诸塞眼科耳科诊所 | 内耳支持细胞的扩增和分化及其使用方法 |
| KR20190098998A (ko) | 2016-12-16 | 2019-08-23 | 파이프라인 테라퓨틱스, 아이엔씨. | 달팽이관 시냅스질환의 치료 방법 |
| WO2020112883A1 (en) | 2018-11-30 | 2020-06-04 | Massachusetts Eye And Ear Infirmary | Inhibition of lysine demethylase 1 (lsd1) induces differentiation of hair cells |
-
2013
- 2013-09-06 AU AU2013312358A patent/AU2013312358B2/en active Active
- 2013-09-06 WO PCT/US2013/058446 patent/WO2014039781A1/en not_active Ceased
- 2013-09-06 JP JP2015531223A patent/JP2015527398A/ja not_active Withdrawn
- 2013-09-06 EP EP21190313.3A patent/EP3970725B1/en active Active
- 2013-09-06 EP EP13836099.5A patent/EP2892506B1/en active Active
- 2013-09-06 HK HK16100053.6A patent/HK1211875A1/xx unknown
- 2013-09-06 CA CA2883896A patent/CA2883896C/en active Active
- 2013-09-06 US US14/426,629 patent/US20150209367A1/en not_active Abandoned
-
2018
- 2018-06-13 US US16/007,586 patent/US10898492B2/en active Active
-
2019
- 2019-05-14 JP JP2019091552A patent/JP2019172679A/ja not_active Withdrawn
-
2020
- 2020-10-28 JP JP2020180340A patent/JP2021038228A/ja not_active Withdrawn
- 2020-12-10 US US17/118,111 patent/US12161647B2/en active Active
-
2022
- 2022-04-20 JP JP2022069599A patent/JP2022109965A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021038228A5 (enExample) | ||
| JP2019172679A5 (enExample) | ||
| JPH08510479A (ja) | 眼の炎症障害を処置するための3‐ベンゾイルフェニル酢酸誘導体を含む局所的に投与可能な組成物 | |
| JP6720301B2 (ja) | 脳のヘミチャネルを遮断するためのアミトリプチリンの使用及びその効果をin vivoで増強する方法 | |
| JP2022109965A (ja) | 聴覚喪失治療 | |
| JPH11512438A (ja) | 末梢性活性抗痛覚過敏オピエート | |
| JP2019503386A5 (enExample) | ||
| JP2013516488A (ja) | 炭酸脱水酵素阻害薬およびさらなる活性剤の組み合わせによる閉塞型睡眠時無呼吸症候群の治療 | |
| JP7132277B2 (ja) | スミス‐マゲニス症候群を治療するためのタシメルテオン | |
| JP2004518653A (ja) | 不安障害を治療する方法 | |
| JP2002520277A (ja) | 不眠症を治療する方法 | |
| BRPI0609915A2 (pt) | métodos para tratar aterosclerose | |
| JP2012526832A (ja) | トランスノルセルトラリン及びセロトニン受容体1a作動剤/拮抗剤を含む組成物及びその使用 | |
| HUP0100998A2 (hu) | (2E)-5-amino-5-metil-hex-2-én-sav-N-metil-N-{(1R)-1-[N-metil-N-/(1R)-1-(metil-karbamoil)-2-fenil-etil/-karbamoil]-2-(2-naftil)-etil}-amid-sók, eljárás azok előállítására, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| US20250144116A1 (en) | Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa | |
| JP2009514961A (ja) | アンギオテンシンii受容体ブロッカー、カルシウムチャネルブロッカーおよび他の活性剤の組合せ | |
| CN116887823A (zh) | 用于外用施用加巴喷丁类药物的方法和制剂 | |
| JP2005500400A5 (enExample) | ||
| US6462089B1 (en) | Method for correcting the vigilance disorders associated with myopathies | |
| US20250170114A1 (en) | Methods of treatment using t-type calcium channel modulators | |
| EP2004167A1 (en) | Renin inhibitors for the treatment of hypertension | |
| US20240358668A1 (en) | Methods and compisitions for ameliorating biomarkers associated with cardiovascualr risk using (r)-2-amino-3-phenylpropyl carbamate | |
| WO2019071272A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY (ADHD) | |
| US8957098B2 (en) | Use of leflunomide and malononitrilamides | |
| EP3743059B1 (fr) | Dérivés aminoacides contenant un groupement disulfanyle sous forme d'un inhibiteur de nep et d'apn pour la prévention et le traitement des douleurs relatives au nerf trijumeau |